Atlas Trials

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Clinical trial NCT06062563 · UNKNOWN

Trial details

NCT number
NCT06062563
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Start date
2023-11-11
Primary completion
2024-12-20
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.